Ensuring that injectable bicarbonate-buffered lidocaine-epinephrine complies with 2015 United States Pharmacopeia (USP) compounding provisions - 20/07/16
Doi : 10.1016/j.jaad.2016.03.051
Prescilia Isedeh, MD a, M. Laird Forrest, PhD b, Deede Liu, MD a, Daniel Aires, MD, JD a, ⁎ 
a Division of Dermatology, University of Kansas Medical Center, Kansas City, Kansas
b Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas
∗Reprint requests: Daniel Aires, MD, JD, Division of Dermatology, University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66103.Division of DermatologyUniversity of Kansas Medical Center3901 Rainbow BlvdKansas CityKS66103
Key words : bicarbonate-buffered lidocaine-epinephrine, compounded sterile preparations, International Organization for Standardization class, microbial risk, United States Pharmacopeia
Il testo completo di questo articolo è disponibile in PDF.
| This piece received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Dr Forrest's efforts were funded in part by National Institutes of Health grants NCI 1R01CA173292 and FDA 1U01FD005285. |
|
| Conflicts of interest: None declared. |
© 2016
American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 75 - N° 2
P. 454-455 - agosto 2016 Ritorno al numero
Articolo precedente
- Early-onset stroke, polyarteritis nodosa (PAN), and livedo racemosa
- Dominique C. Pichard, Amanda K. Ombrello, Patrycja Hoffmann, Deborah L. Stone, Edward W. Cowen
- Correction
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?